Patients with Congenital Bleeding Disorders Appear to be Less Severely Affected by SARS-CoV-2: Is Inherited Hypocoagulability Overcoming Acquired Hypercoagulability of Coronavirus Disease 2019 (COVID-19)?

Dorgalaleh, Akbar; Dabbagh, Ali; Tabibian, Shadi; Baghaeipour, M R; Jazebi, Mohammad; Bahraini, Mehran; Fazeli, Alieh; Rad, Fariba; Baghaeipour, Nazanin

doi:10.1055/s-0040-1713435

Cited by 26 publications

(52 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The majority of individuals infected with SARS-CoV-2 are generally asymptomatic, although the most common symptoms of COVID-19 include dry cough, fever, dyspnea, chest pain, headache, and muscle ache 11 , 12 . The issue of hypercoagulability-related thrombotic vascular events in those infected with SARS-CoV-2 is emerging 13 , 14 . Evidence suggests that COVID-19 patients may experience increased rates of thromboembolism, as high as 15%–26% 15 .…”

Section: Introductionmentioning

confidence: 99%

Hemorrhagic and ischemic stroke in patients with coronavirus disease 2019: incidence, risk factors, and pathogenesis - a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Background: In this study, we aimed to determine the global prevalence, chronological order of symptom appearance, and mortality rates with regard to hemorrhagic and ischemic stroke in patients with coronavirus disease 2019 (COVID-19) and to discuss possible pathogeneses of hemorrhagic and ischemic stroke in individuals with the disease. Methods: We searched the PubMed, Scopus, and Web of Science databases for relevant articles published up to November 8, 2020. Data regarding study characteristics, hemorrhagic stroke, ischemic stroke, and COVID-19 were retrieved in accordance with the PRISMA guidelines. The Newcastle-Ottawa scale was used to assess the quality of the eligible studies. The pooled prevalence and mortality rate of hemorrhagic and ischemic stroke were calculated. Results: The pooled estimate of prevalence of hemorrhagic stroke was 0.46% (95% CI 0.40%–0.53%; I2=89.81%) among 67,155 COVID-19 patients and that of ischemic stroke was 1.11% (95% CI 1.03%–1.22%; I2=94.07%) among 58,104 COVID-19 patients. Ischemic stroke was more predominant (incidence: 71.58%) than hemorrhagic stroke (incidence: 28.42%) in COVID-19 patients who experienced a stroke. In COVID-19 patients who experienced a stroke, hospital admission with respiratory symptoms was more commonly reported than that with neurological symptoms (20.83% for hemorrhagic stroke and 5.51% for ischemic stroke versus 6.94% for hemorrhagic stroke and 5.33% for ischemic stroke, respectively). The pooled mortality rate of COVID-19 patients who experienced a hemorrhagic and ischemic stroke was 44.72% (95% CI 36.73%–52.98%) and 36.23% (95% CI 30.63%–42.24%), respectively. Conclusions: Although the occurrence of hemorrhagic and ischemic stroke is low, the mortality rates of both stroke types in patients with COVID-19 are concerning, and therefore, despite several potential pathogeneses that have been proposed, studies aimed at definitively elucidating the mechanisms of hemorrhagic and ischemic stroke in individuals with COVID-19 are warranted. PROSPERO registration: CRD42020224470 (04/12/20)

show abstract

Section: Introductionmentioning

confidence: 99%

Hemorrhagic and ischemic stroke in patients with coronavirus disease 2019: incidence, risk factors, and pathogenesis - a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Clinically diagnosis of COVID‐19 may be difficult since the clinical manifestations of COVID‐19 are very similar to that of various viral infections 6 . In addition, studies have reported laboratory features of COVID‐19 patients 7 . However, unfortunately, these studies are limited to one or few blood indicators.…”

Section: Introductionmentioning

confidence: 99%

COVID‐19 and hematology findings based on the current evidences: A puzzle with many missing pieces

Karimi‐Shahri

Niazkar

Rad

2020

Int J Lab Hematology

Self Cite

View full text Add to dashboard Cite

In December 2019, a new type of coronavirus was detected for the first time in Wuhan, Hubei Province, China. According to the reported data, the emerging coronavirus has spread worldwide, infecting more than fifty‐seven million individuals, leading to more than one million deaths. The current study aimed to review and discuss the hematological findings of COVID‐19. Laboratory changes and hematologic abnormalities have been reported repeatedly in COVID‐19 patients. WBC count and peripheral blood lymphocytes are normal or slightly reduced while these indicators may change with the progression of the disease. In addition, several studies demonstrated that decreased hemoglobin levels in COVID‐19 patients were associated with the severity of the disease. Moreover, thrombocytopenia, which is reported in 5%‐40% of patients, is known to be associated with poor prognosis of the disease. COVID‐19 can present with various hematologic manifestations. In this regard, accurate evaluation of laboratory indicators at the beginning and during COVID‐19 can help physicians to adjust appropriate treatment and provide special and prompt care for those in need.

show abstract

“…Hypercoagulability is a common feature of SARS-CoV-2 infection, but the impact of the infection on CBD patients is still unknown. In the literature, the possibility of thromboembolic disorders in this group of patients, a thrombotic episode in a patient with mild VWF disease [ 19 ] and the possibility of bleeding associated with SARS-CoV-2 infection [ 20 ] have all been reported. All the while there is a discussion about a possible association between complications and the level of factor VWF [ 21 , 22 ].…”

Section: Resultsmentioning

confidence: 99%

“…The impact of COVID-19 on the health of patients with congenital bleeding disorders (CBD) is still under discussion. The literature suggests the possibility of thromboembolic disorders, also in patients with CBD [ 19 ]. There are known cases of bleeding related to COVID-19 infection [ 20 ] and also the influence of VWF factor level on the risk of complications is discussed [ 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

Practical Recommendations for Treatment of Dental Patients with Congenital Bleeding Disorders during the Covid-19 Pandemic: A Narrative Review

Czajkowska

Rupa‐Matysek

Gil

et al. 2020

IJERPH

View full text Add to dashboard Cite

At the end of 2019, a new disease—COVID-19—was identified, and a few months later, the World Health Organization announced a pandemic. It is now known that SARS-CoV-2 is highly contagious and most confirmed infections are mild to moderate. The situation is particularly difficult for dentists due to the high risk of virus transmission in the dental surgery. Complications including, but not limited to, problems with the respiratory and cardiovascular systems have been reported in patients with SARS-CoV-2. Several changes in the coagulation system, such as lower platelet numbers or increased prothrombin time, as well as increased D-dimer and fibrinogen, were observed. This review is intended to systematize the knowledge on the treatment of patients with congenital bleeding disorders (CBD) during the SARS-CoV-2 pandemic. Extensive literature research was conducted into COVID-19 and the general medical and dental treatment of patients with CBD. Case studies, research results and recommendations of international societies were used in the study. The results of this research are presented in the form of recommendations for the treatment of patients with coagulopathies. It should be remembered that the impact of COVID-19 on the health condition of patients with CBD is unknown to date.

show abstract

Patients with Congenital Bleeding Disorders Appear to be Less Severely Affected by SARS-CoV-2: Is Inherited Hypocoagulability Overcoming Acquired Hypercoagulability of Coronavirus Disease 2019 (COVID-19)?

Abstract: Letter to the Editor 853 This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.

Cited by 26 publications

References 15 publications

Hemorrhagic and ischemic stroke in patients with coronavirus disease 2019: incidence, risk factors, and pathogenesis - a systematic review and meta-analysis

Hemorrhagic and ischemic stroke in patients with coronavirus disease 2019: incidence, risk factors, and pathogenesis - a systematic review and meta-analysis

COVID‐19 and hematology findings based on the current evidences: A puzzle with many missing pieces

Practical Recommendations for Treatment of Dental Patients with Congenital Bleeding Disorders during the Covid-19 Pandemic: A Narrative Review

Contact Info

Product

Resources

About